Welcome to our dedicated page for Ares Capital Corporation news (Ticker: $ARCC), a resource for investors and traders seeking the latest updates and insights on Ares Capital Corporation stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ares Capital Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ares Capital Corporation's position in the market.
Ares Capital (ARCC) has priced a public offering of $850 million 5.950% unsecured notes due 2029. The notes mature on July 15, 2029, with options for redemption. Various institutions are involved in managing the offering. The proceeds will be used to repay existing debt and for general corporate purposes, including investments in portfolio companies.
Ares Capital announced its Q1 2024 financial results with a dividend of $0.48 per share for Q2 2024. The company reported a strong start to the year with increased earnings, low non-accruals, and moderate leverage. Ares Capital made $3.6 billion in new investment commitments in Q1 2024 and continues to support growth in existing portfolio companies. The company remains well-positioned with available capital and competitive advantages.
